The gsp oncogene disrupts Ras/ERK-dependent prolactin gene regulation in gsp inducible somatotroph cell line

Endocrinology

Volumn 152, Issue 4, 2011, Pages 1234-1243

  Pertuit, M ^a   Romano, D ^b   Zeiller, C ^a   Barlier, A ^a,c   Enjalbert, A ^a,c   Gerard, C ^a  

^a AIX MARSEILLE UNIVERSITY   (France)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

^c TIMONE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC AMP DEPENDENT PROTEIN KINASE; GROWTH HORMONE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PROLACTIN; RAP1 PROTEIN; RAS PROTEIN; STIMULATORY GUANINE NUCLEOTIDE BINDING PROTEIN; STRESS ACTIVATED PROTEIN KINASE;

ARTICLE; CELL LINE; ENZYME ACTIVATION; ENZYME ACTIVITY; GENE CONTROL; GENE EXPRESSION; GROWTH HORMONE SECRETING ADENOMA; GROWTH HORMONE SECRETING CELL; ONCOGENE; PRIORITY JOURNAL; PROMOTER REGION;

ANIMALS; BUTADIENES; ENZYME ACTIVATION; ENZYME INHIBITORS; GTP-BINDING PROTEIN ALPHA SUBUNITS, GS; HUMANS; ISOQUINOLINES; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; NITRILES; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PROTO-ONCOGENE PROTEINS P21(RAS); RAP1 GTP-BINDING PROTEINS; RATS; SULFONAMIDES; VASOACTIVE INTESTINAL PEPTIDE;

EID: 79953184267     PISSN: 00137227     EISSN: 00137227     Source Type: Journal    
DOI: 10.1210/en.2010-1077     Document Type: Article

References (53)

1. Garrington TP, Johnson GL 1999 Organization and regulation of mitogen-activated protein kinase signaling pathways. Curr Opin Cell Biol 11:211-218 (Pubitemid 29164036)
2. Gutkind JS 2000 Regulation of mitogen-activated protein kinase signaling networks by G protein-coupled receptors. Sci STKE 2000:re1
3. Goldsmith ZG, Dhanasekaran DN 2007 G protein regulation of MAPK networks. Oncogene 26:3122-3142 (Pubitemid 46763010)
4. Lawrence MC, Jivan A, Shao C, Duan L, Goad D, Zaganjor E, Osborne J, McGlynn K, Stippec S, Earnest S, Chen W, Cobb MH 2008 The roles of MAPKs in disease. Cell Res 18:436-442 (Pubitemid 351498850)
5. Dhillon AS, Hagan S, Rath O, Kolch W 2007 MAP kinase signalling pathways in cancer. Oncogene 26:3279-3290 (Pubitemid 46763021)
6. Shimon I, Melmed S 1997 Genetic basis of endocrine disease: pituitary tumor pathogenesis. J Clin Endocrinol Metab 82:1675-1681
7. Lania A, Mantovani G, Spada A 2003 Genetics of pituitary tumors: focus on G-protein mutations. Exp Biol Med (Maywood) 228:1004-1017 (Pubitemid 37222168)
8. Spada A, Lania A, Mantovani G 2007 Hormonal signaling and pituitary adenomas. Neuroendocrinology 85:101-109 (Pubitemid 46725696)
9. Vallar L, Spada A, Giannattasio G 1987 Altered Gs and adenylate cyclase activity in human GH-secreting pituitary adenomas. Nature 330:566-568 (Pubitemid 17164352)
10. Landis CA, Masters SB, Spada A, Pace AM, Bourne HR, Vallar L 1989 GTPase inhibiting mutations activate the α chain of Gs and stimulate adenylyl cyclase in human pituitary tumours. Nature 340:692-696 (Pubitemid 19214389)
11. Hamacher C, Bröcker M, Adams EF, Lei T, Fahlbusch R, Buchfelder M, Derwahl M 1998 Overexpression of stimulatory G protein α-subunit is a hallmark of most human somatotrophic pituitary tumours and is associated with resistance to GH-releasing hormone. Pituitary 1:13-23 (Pubitemid 128512309)
12. Picard C, Silvy M, Gerard C, Buffat C, Lavaque E, Figarella-Branger D, Dufour H, Gabert J, Beckers A, Brue T, Enjalbert A, Barlier A 2007 Gsα overexpression and loss of Gsα imprinting in human somatotroph adenomas: association with tumor size and response to pharmacologic treatment. Int J Cancer 121:1245-1252 (Pubitemid 47293791)
13. Lania AG, Mantovani G, Ferrero S, Pellegrini C, Bondioni S, Peverelli E, Braidotti P, Locatelli M, Zavanone ML, Ferrante E, Bosari S, Beck-Peccoz P, Spada A 2004 Proliferation of transformed somatotroph cells related to low or absent expression of protein kinase a regulatory subunit 1A protein. Cancer Res 64:9193-9198 (Pubitemid 40003794)
14. Wang YH, Maurer RA 1999 A role for the mitogen-activated protein kinase in mediating the ability of thyrotropin-releasing hormone to stimulate the prolactin promoter. Mol Endocrinol 13:1094-1104 (Pubitemid 30644298)
15. Wang YH, Jue SF, Maurer RA 2000 Thyrotropin-releasing hormone stimulates phosphorylation of the epidermal growth factor receptor in GH3 pituitary cells. Mol Endocrinol 14:1328-1337
16. Kanasaki H, Yonehara T, Yamamoto H, Takeuchi Y, Fukunaga K, Takahashi K, Miyazaki K, Miyamoto E 2002 Differential regulation of pituitary hormone secretion and gene expression by thyrotropin-releasing hormone. A role for mitogen-activated protein kinase signaling cascade in rat pituitary GH3 cells. Biol Reprod 67:107-113
17. Pickett CA, Gutierrez-Hartmann A 1994 Ras mediates Src but not epidermal growth factor-receptor tyrosine kinase signaling pathways in GH4 neuroendocrine cells. Proc Natl Acad Sci USA 91:8612-8616 (Pubitemid 24273714)
18. Castillo AI, Tolon RM, Aranda A 1998 Insulin-like growth factor-1 stimulates rat prolactin gene expression by a Ras, ETS and phosphatidylinositol 3-kinase dependent mechanism. Oncogene 16:1981-1991
19. Romano D, Pertuit M, Rasolonjanahary R, Barnier JV, Magalon K, Enjalbert A, Gerard C 2006 Regulation of the RAP1/RAF-1/extracellularly regulated kinase-1/2 cascade and prolactin release by the phosphoinositide 3-kinase/AKT pathway in pituitary cells. Endocrinology 147:6036-6045 (Pubitemid 44833523)
20. Houslay MD, Kolch W 2000 Cell-type specific integration of crosstalk between extracellular signal-regulated kinase and cAMP signaling. Mol Pharmacol 58:659-668
21. Stork PJ, Schmitt JM 2002 Crosstalk between cAMP and MAP kinase signaling in the regulation of cell proliferation. Trends Cell Biol 12:258-266 (Pubitemid 34634174)
22. Dumaz N, Marais R 2005 Integrating signals between cAMP and the RAS/RAF/MEK/ERK signalling pathways. Based on the anniversary prize of the Gesellschaft fur Biochemie und Molekularbiologie Lecture delivered on 5 July 2003 at the Special FEBS Meeting in Brussels. FEBS J 272:3491-3504
23. Le Péchon-Vallée C, Magalon K, Rasolonjanahary R, Enjalbert A, Gérard C 2000 Vasoactive intestinal polypeptide and pituitary adenylate cyclase-activating polypeptides stimulate mitogen-activated protein kinase in the pituitary cell line GH4C1 by a 3′,5′-cyclic adenosine monophosphate pathway. Neuroendocrinology 72:46-56 (Pubitemid 30665973)
24. Kievit P, Lauten JD, Maurer RA 2001 Analysis of the role of the mitogen-activated protein kinase in mediating cyclic-adenosine 3′,5′-monophosphate effects on prolactin promoter activity. Mol Endocrinol 15:614-624 (Pubitemid 32324442)
25. Yonehara T, Kanasaki H, Yamamoto H, Fukunaga K, Miyazaki K, Miyamoto E 2001 Involvement of mitogen-activated protein kinase in cyclic adenosine 3′,5′-monophosphate-induced hormone gene expression in rat pituitary GH(3) cells. Endocrinology 142:2811-2819 (Pubitemid 32575516)
26. Romano D, Magalon K, Ciampini A, Talet C, Enjalbert A, Gerard C 2003 Differential involvement of the Ras and Rap1 small GTPases in vasoactive intestinal and pituitary adenylyl cyclase activating polypeptides control of the prolactin gene. J Biol Chem 278:51386-51394 (Pubitemid 38020378)
27. Pertuit M, Barlier A, Enjalbert A, Gérard C 2009 Signalling pathway alterations in pituitary adenomas: involvement of Gsα, cAMP and mitogen-activated protein kinases. J Neuroendocrinol 21:869-877
28. Lania A, Filopanti M, Corbetta S, Losa M, Ballaré E, Beck-Peccoz P, Spada A 2003 Effects of hypothalamic neuropeptides on extracellular signal-regulated kinase (ERK1 and ERK2) cascade in human tumoral pituitary cells. J Clin Endocrinol Metab 88:1692-1696 (Pubitemid 36623390)
29. Mantovani G, Bondioni S, Ferrero S, Gamba B, Ferrante E, Peverelli E, Corbetta S, Locatelli M, Rampini P, Beck-Peccoz P, Spada A, Lania AG 2005 Effect of cyclic adenosine 3′,5′-monophosphate/protein kinase a pathway on markers of cell proliferation in non-functioning pituitary adenomas. J Clin Endocrinol Metab 90:6721-6724 (Pubitemid 41759338)
30. Robinson-White A, Hundley TR, Shiferaw M, Bertherat J, Sandrini F, Stratakis CA 2003 Protein kinase-A activity in PRKAR1A-mutant cells, and regulation of mitogen-activated protein kinases ERK1/2. Hum Mol Genet 12:1475-1484 (Pubitemid 36857296)
31. Romano D, Magalon K, Pertuit M, Rasolonjanahary R, Barlier A, Enjalbert A, Gerard C 2007 Conditional overexpression of the wild-type Gsα as the gsp oncogene initiates chronic extracellularly regulated kinase 1/2 activation and hormone hypersecretion in pituitary cell lines. Endocrinology 148:2973-2983 (Pubitemid 46984797)
32. Gossen M, Bujard H 1992 Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci USA 89:5547-5551
33. Meloche S, Pagès G, Pouysségur J 1992 Functional expression and growth factor activation of an epitope-tagged p44 mitogen-activated protein kinase, p44mapk. Mol Biol Cell 3:63-71 (Pubitemid 23094252)
34. Bouschet T, Perez V, Fernandez C, Bockaert J, Eychene A, Journot L 2003 Stimulation of the ERK pathway by GTP-loaded Rap1 requires the concomitant activation of Ras, protein kinase C, and protein kinase A in neuronal cells. J Biol Chem 278:4778-4785 (Pubitemid 36800980)
35. Wolthuis RM, de Ruiter ND, Cool RH, Bos JL 1997 Stimulation of gene induction and cell growth by the Ras effector Rlf. EMBO J 16:6748-6761 (Pubitemid 27503487)
36. Pickett CA, Gutierrez-Hartmann A 1995 Epidermal growth factor and Ras regulate gene expression in GH4 pituitary cells by separate, antagonistic signal transduction pathways. Mol Cell Biol 15:6777-6784
37. Harris PE, Alexander JM, Bikkal HA, Hsu DW, Hedley-Whyte ET, Klibanski A, Jameson JL 1992 Glycoprotein hormone α-subunit production in somatotroph adenomas with and without Gsα mutations. J Clin Endocrinol Metab 75:918-923
38. Gaiddon C, Mercken L, Bancroft C, Loeffler JP 1995 Transcriptional effects in GH3 cells of Gsα mutants associated with human pituitary tumors: stimulation of adenosine 3′,5′-monophosphate response element-binding protein-mediated transcription and of prolactin and growth hormone promoter activity via protein kinase A. Endocrinology 136:4331-4338
39. Ham J, Ivan M, Wynford-Thomas D, Scanlon MF 1997 GH3 cells expressing constitutively active Gsα (Q227L) show enhanced hormone secretion and proliferation. Mol Cell Endocrinol 127:41-47
40. Tian J, Chen J, Bancroft C 1994 Expression of constitutively active Gsα-subunits in GH3 pituitary cells stimulates prolactin promoter activity. J Biol Chem 269:33-36
41. Ooi GT, Tawadros N, Escalona RM 2004 Pituitary cell lines and their endocrine applications. Mol Cell Endocrinol 228:1-21 (Pubitemid 39482516)
42. Marshall CJ 1995 Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell 80:179-185
43. Kao S, Jaiswal RK, Kolch W, Landreth GE 2001 Identification of the mechanisms regulating the differential activation of the mapk cascade by epidermal growth factor and nerve growth factor in PC12 cells. J Biol Chem 276:18169-18177
44. Murphy LO, Blenis J 2006 MAPK signal specificity: the right place at the right time. Trends Biochem Sci 31:268-275 (Pubitemid 43674354)
45. Gerits N, Kostenko S, Shiryaev A, Johannessen M, Moens U 2008 Relations between the mitogen-activated protein kinase and the cAMP-dependent protein kinase pathways: comradeship and hostility. Cell Signal 20:1592-1607
46. Li Y, Asuri S, Rebhun JF, Castro AF, Paranavitana NC, Quilliam LA 2006 The RAP1 guanine nucleotide exchange factor Epac2 couples cyclic AMP and Ras signals at the plasma membrane. J Biol Chem 281:2506-2514 (Pubitemid 43845710)
47. Liu C, Takahashi M, Li Y, Song S, Dillon TJ, Shinde U, Stork PJ 2008 Ras is required for the cyclic AMP-dependent activation of Rap1 via Epac2. Mol Cell Biol 28:7109-7125
48. Sasagawa S, Ozaki Y, Fujita K, Kuroda S 2005 Prediction and validation of the distinct dynamics of transient and sustained ERK activation. Nat Cell Biol 7:365-373 (Pubitemid 40533125)
49. Karga HJ, Alexander JM, Hedley-Whyte ET, Klibanski A, Jameson JL 1992 Ras mutations inhumanpituitary tumors. J Clin Endocrinol Metab 74:914-919
50. Lin Y, Jiang X, Shen Y, Li M, Ma H, Xing M, Lu Y 2009 Frequent mutations and amplifications of the PIK3CA gene in pituitary tumors. Endocr Relat Cancer 16:301-310
51. Adams EF, Lei T, Buchfelder M, Petersen B, Fahlbusch R 1995 Biochemical characteristics of human pituitary somatotropinomas with and without gsp mutations: in vitro cell culture studies. J Clin Endocrinol Metab 80:2077-2081
52. Barlier A, Gunz G, Zamora AJ, Morange-Ramos I, Figarella-Branger D, Dufour H, Enjalbert A, Jaquet P 1998 Pronostic and therapeutic consequences of Gsα mutations in somatotroph adenomas. J Clin Endocrinol Metab 83:1604-1610 (Pubitemid 28501029)
53. Bhayana S, Booth GL, Asa SL, Kovacs K, Ezzat S 2005 The implication of somatotroph adenoma phenotype to somatostatin analog responsiveness in acromegaly. J Clin Endocrinol Metab 90:6290-6295